Rousseau, E; Palm, T; Scaravilli, F; Ruchoux, MM; Figarella-Branger, D; Salmon, I; Ellison, D; ... Godfraind, C; + view all Rousseau, E; Palm, T; Scaravilli, F; Ruchoux, MM; Figarella-Branger, D; Salmon, I; Ellison, D; Lacroix, C; Chapon, F; Mikol, J; Vikkula, M; Godfraind, C; - view fewer (2007) Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Molecular Cancer , 6 , Article 47. 10.1186/1476-4598-6-47.

Preview

PDF 1476-4598-6-47.pdf Download (2MB)

Abstract

Ependymal tumors constitute a clinicopathologically heterogeneous group of brain tumors. They vary in regard to their age at first symptom, localization, morphology and prognosis. Genetic data also suggests heterogeneity. We define a newly recognized subset of ependymal tumors, the trisomy 19 ependymoma. Histologically, they are compact lesions characterized by a rich branched capillary network amongst which tumoral cells are regularly distributed. When containing clear cells they are called clear cell ependymoma. Most trisomy 19 ependymomas are supratentorial WHO grade III tumors of the young. Genetically, they are associated with trisomy 19, and frequently with a deletion of 13q21.31-31.2, three copies of 11q13.3-13.4, and/or deletions on chromosome 9. These altered chromosomal regions are indicative of genes and pathways involved in trisomy 19 ependymoma tumorigenesis. Recognition of this genetico-histological entity allows better understanding and dissection of ependymal tumors.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item